Growth hormone protects colorectal cancer cells from radiation by improving the ability of DNA damage repair

Wu,Xiao‑Yu; Chen,Che; Yao,Xue‑Quan; Cao,Qin‑Hong; Xu,Zhe; Li,Wei‑Su; Liu,Fu‑Kun; Li,Gang

doi:10.3892/mmr.2014.2185

Growth hormone protects colorectal cancer cells from radiation by improving the ability of DNA damage repair

Authors:
- Xiao‑Yu Wu
- Che Chen
- Xue‑Quan Yao
- Qin‑Hong Cao
- Zhe Xu
- Wei‑Su Li
- Fu‑Kun Liu
- Gang Li
View Affiliations

Affiliations: Department of Gastrointestinal Tumor Surgery, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of General Surgery, Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China
Published online on: April 24, 2014 https://doi.org/10.3892/mmr.2014.2185
Pages: 486-490

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine the effects of recombinant human growth hormone (rhGH) on the sensitivity of a colorectal cancer cell line to radiotherapy, and to investigate its association with DNA damage and repair. Flow cytometry and immunofluorescence were employed to detect growth hormone receptor (GHR) expression in nine human colorectal cancer cell lines. A colony forming assay was performed to measure the colorectal cancer cell proliferation post‑radiotherapy, as an indicator of radiotherapy sensitivity. The comet assay results were interpreted as an indicator of radiotherapy‑induced DNA damage, and growth arrest and DNA damage 45 (GADD45) and apurinic/apyrimidinic endonuclease (APEN) protein expression were quantified with western blot analysis from the same cell lines. The results demonstrated that the colony‑forming efficiency (CFE) was significantly increased in HCT‑8 cells subject to radiotherapy and rhGH pretreatment compared with the cells treated with radiotherapy alone, in a dose‑dependent manner (0‑100 mg/l). This effect was enhanced under high doses of radiation (8 Gy; 52.1±2.9 vs. 21.0±2.7; P<0.001) and was ameliorated with GHR neutralizing antibody exposure. By contrast, rhGH pre‑incubation did not change the colony formation rate in GHR(‑) LOVO cells. rhGH intervention reduced the early HCT‑8 cell DNA damage (21.53±2.88 vs. 36.56±3.93; P=0.003) as well as the following plateau phase, compared with cells treated with radiotherapy alone (5.5±0.42 vs. 9.07±0.84; P=0.012). rhGH upregulated GADD45 and APEN protein expression, which is associated with cellular stress responses and DNA damage repair (P=0.007). The results suggest that rhGH is able to protect colorectal cancer cells from radiation through the interaction with GHR, which is associated with the promotion of DNA damage repair activity.

View Figures

View References

1	Wu X, Wan M, Li G, Xu Z, et al: Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. Eur J Cancer. 42:888–894. 2006. View Article : Google Scholar : PubMed/NCBI
2	Madrid O, Varea S, Sanchez-Perez I, et al: Growth hormone protects against radiotherapy-induced cell death. Eur J Endocrinol. 147:535–541. 2002. View Article : Google Scholar : PubMed/NCBI
3	Isla A, Budke M, García-Grande A, et al: Protective effects of the growth hormone (GH) on the irradiated spinal cord in rats. Neurocirugia (Astur). 18:89–94. 2007.(In Spanish).
4	Isla A, Budke M, Cacicedo L, et al: Protective effects of growth hormone in cell cultures of the central nervous system. Rev Neurol. 34:208–211. 2002.(In Spanish).
5	Bougen NM, Steiner M, Pertziger M, et al: Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. Endocr Relat Cancer. 19:625–644. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dunne AL, Price ME, Mothersill C, et al: Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. Br J Cancer. 89:2277–2283. 2003. View Article : Google Scholar
7	Rojas E, Lopez MC and Valverde M: Single cell gel electrophoresis assay: methodology and applications. J Chromatogr B Biomed Sci Appl. 722:225–254. 1999. View Article : Google Scholar : PubMed/NCBI
8	Collins AR: The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol. 26:249–261. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lee E, Oh E and Lee J, Sul D and Lee J: Use of the tail moment of the lymphocytes to evaluate DNA damage in human biomonitoring studies. Toxicol Sci. 81:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
10	Fuh G, Cunningham BC, Fukunaga R, et al: Rational design of potent antagonists to the human growth hormone receptor. Science. 256:1677–1680. 1992. View Article : Google Scholar : PubMed/NCBI
11	Willers H, Dahm-Daphi J and Powell SN: Repair of radiation damage to DNA. Br J Cancer. 90:1297–1301. 2004. View Article : Google Scholar : PubMed/NCBI
12	Thompson BJ, Shang CA and Waters MJ: Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology. 141:4321–4324. 2000. View Article : Google Scholar : PubMed/NCBI
13	Wang XW, Zhan Q, Coursen JD, et al: GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA. 96:3706–3711. 1999. View Article : Google Scholar : PubMed/NCBI
14	Liebermann DA and Hoffman B: Gadd45 in stress signaling. J Mol Signal. 3:152008. View Article : Google Scholar : PubMed/NCBI
15	Fishel ML and Kelley MR: The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med. 28:375–395. 2007. View Article : Google Scholar : PubMed/NCBI
16	Argetsinger LS and Carter-Su C: Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. Horm Res. 45(Suppl 1): 22–24. 1996. View Article : Google Scholar : PubMed/NCBI
17	Love DW, Whatmore AJ, Clayton PE and Silva CM: Growth hormone stimulation of the mitogen-activated protein kinase pathway is cell type specific. Endocrinology. 139:1965–1971. 1998.PubMed/NCBI
18	Möller C, Hansson A, Enberg B, et al: Growth hormone (GH) induction of tyrosine phosphorylation and activation of mitogen-activated protein kinases in cells transfected with rat GH receptor cDNA. J Biol Chem. 267:23403–23408. 1992.PubMed/NCBI
19	Argetsinger LS, Hsu GW, Myers MG Jr, et al: Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J Biol Chem. 270:14685–14692. 1995. View Article : Google Scholar
20	Argetsinger LS, Norstedt G, Billestrup N, et al: Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signalling. J Biol Chem. 271:29415–29421. 1996. View Article : Google Scholar
21	Jeay S, Sonenshein GE, Kelly PA, et al: Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kappaB and phosphatidylinositol 3-kinase. Endocrinology. 142:147–156. 2001.
22	VanderKuur J, Allevato G, Billestrup N, et al: Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2. J Biol Chem. 270:7587–7593. 1995. View Article : Google Scholar : PubMed/NCBI
23	Argetsinger LS and Carter-Su C: Mechanism of signalling by growth hormone receptor. Physiol Rev. 76:1089–1107. 1996.PubMed/NCBI
24	Wang YD and Wood WI: Amino acids of the human growth hormone receptor that are required for proliferation and Jak-STAT signalling. Mol Endocrinol. 9:303–311. 1995.PubMed/NCBI
25	Pircher TJ, Flores-Morales A, Mui AL, et al: Mitogen-activated protein kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5. Mol Cell Endocrinol. 133:169–176. 1997. View Article : Google Scholar : PubMed/NCBI
26	Ihle JN, Witthuhn BA, Quelle FW, et al: Signalling through the hematopoietic cytokine receptors. Ann Rev Immunol. 13:369–398. 1995. View Article : Google Scholar : PubMed/NCBI
27	Drake WM and Trainer PJ: Clinical use of pegvisomant for the treatment of acromegaly. Treat Endocrinol. 2:369–374. 2003. View Article : Google Scholar : PubMed/NCBI